OncoMatch/Clinical Trials/NCT05412589
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Is NCT05412589 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies mFOLFOX7+Camrelizumab+Apatinib for stage iii hepatocellular cancer (cnlc staging).
Treatment: mFOLFOX7+Camrelizumab+Apatinib — This is a prospective, one-arm, phase II clinical study of intravenous mFOLFOX6 plus Camrelizumab combined with apatinib for CNLC stage III hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: immunotherapy
Have received immunotherapeutic drugs or interferon in the past.
Cannot have received: first-line drugs such as Sorafenib (Sorafenib)
Did not received any type of other first-line drugs such as Sorafenib
Lab requirements
Blood counts
White blood cells count ≥3.0×10^9/L; Platelet count ≥70×10^9/L; Hemoglobin ≥80g/L
Kidney function
Serum creatinine (SCr) ≤ 1.5x ULN or creatinine clearance ≥50 ml/min (Cockcroft-Gault formula)
Liver function
Child-pugh liver function grading: Grade A or B; Total bilirubin (TBIL) ≤ 1.5x ULN; AST or ALT ≤ 3x ULN
The function of vital organs meets the following requirements...Blood routine: White blood cells count ≥3.0×10^9/L Platelet count ≥70×10^9/L Hemoglobin ≥80g/L; Liver and kidney function: Serum creatinine (SCr) ≤ 1.5x ULN or creatinine clearance ≥50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 1.5x ULN; AST or ALT ≤ 3x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05412589 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages